Novo Nordisk's Oral Wegovy Surge Masks a Strategic Reset

Novo Nordisk’s Q1 2026 earnings call was a tale of two narratives: a commercial triumph in oral Wegovy and a quiet but profound strategic reset in R&D. Despite an overall adjusted sales decline of 4% (reflecting lower realized prices), the company delivered a blockbuster launch – more than 2 million prescriptions and 1 million+ patients on oral Wegovy within 16 weeks – while simultaneously walking away from a previously touted formulation. The juxtaposition of aggressive commercial expansion and disciplined pipeline curation defines what CEO Mike Doustdar called “focused investments towards growth opportunities.”

Wegovy Pill: The Sweet Spot

The Wegovy high dose approval and the oral Wegovy launch are reshaping the U.S. franchise. EVP Jamey Millar reported a shift in new-to-brand dynamics: “First quarter TRxs were 1.3 million in total, and since launch, we have generated more than 2 million TRxs, translating into more than 1 million people treated.” — Jamey Millar, EVP U.S. Operations · 2026-05-06 The company’s focus on “use, users and usage” has driven a notable share gain, with NBRx market share around 65%.

Pricing remains the cornerstone. CFO Karsten Knudsen noted that while retail sales were robust, a portion was inventory build: “For the Wegovy tablet, we reported around DKK 2.3 billion sales in Q1. To the tune of $150 million of those were related to what we call pipeline filling.” — Karsten Knudsen, CFO or Finance Executive · 2026-05-06 CEO Mike Doustdar reinforced the pricing strategy, stating we are at the sweet spot where volume momentum justifies current prices. This optimism has allowed the company to raise its 2026 guidance by 1 percentage point at both the top and bottom lines.

Pipeline Pivot: CagriSema Co-Formulation Dropped

A major strategic shift came in R&D. Martin Holst Lange, EVP R&D, announced the termination of the CagriSema co-formulation development, opting instead to focus on the dual-chamber device and the emerging oral co formulation alternative. As he explained:

We've always talked about scaling the dual-chamber device of CagriSema to a full-scale launch, and we are very confident in that. We saw the co-formulation as a flexibility or upside option. The way we now think about it is that we have front-loaded and sped up the AMAZE program and the type 2 diabetes program as well as the oral program for zenagamtide. With full scalability on the dual-chamber device combined with anything zenagamtide coming more or less the same time or even before as the co-formulation could, it really didn't make sense to progress. It was not a technical thing - we did see full bioavailability, so it actually worked. There was just no need from a production perspective to progress it.

This decision signals a pivot towards flexible dosing (a key learning from REDEFINE 1) and a broader pipeline that includes the oral GLP-1/GIP/glucagon tri-agonist and other candidates. Meanwhile, the positive Etavopivat data in sickle cell disease – with hemoglobin response rates of 48.7% vs 7.2% and a 27% reduction in annualized VOC rates – adds a rare disease growth leg, a topic CEO Doustdar highlighted when he said the company is “incredibly proud” of the results.

International Expansion and Cost Discipline

While the U.S. story dominates, international operations grew 6% in the quarter, with obesity care sales up 44%. The Wegovy pill is set to launch in select ex U.S. markets later this year, and the company continues to expand its telehealth partnerships. This international momentum echoes the strategy outlined by CEO Mike Doustdar in November 2025: “But our job right now is to focus the company's strategy around diabetes and obesity predominantly because we see a huge expansion potential as we go forward.” — Maziar Doustdar, Chief Executive Officer (CEO) · 2025-11-05 At the same time, Karsten Knudsen emphasized continued cost discipline, noting that FTEs have decreased by nearly 10,000 year-over-year, with savings reinvested into growth: “We are very disciplined and rational – almost 10,000 fewer FTEs today compared to a year ago, reallocating resources toward our key growth opportunities.”

The raised guidance also reflects a better-than-expected run-rate entering 2026, as evidenced in the prior quarter: “So, as to the guidance first, with the International Operations delivering 8% growth in the fourth quarter of last year and around 10% in the second half that's the run rate we are entering 2026.” — Karsten Knudsen, Executive Vice President, Finance · 2026-02-04 Now, with the oral franchise scaling and the pipeline pivot, Novo Nordisk is positioning itself not just as a leader in injected peptides, but as a diversified metabolic powerhouse with a stake in rare disease. The market appears to be listening, though the absence of price action data here means the verdict is still out.